These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29092060)

  • 1. Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease.
    De Rechter S; Bacchetta J; Godefroid N; Dubourg L; Cochat P; Maquet J; Raes A; De Schepper J; Vermeersch P; Van Dyck M; Levtchenko E; D'Haese P; Evenepoel P; Mekahli D
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4210-4217. PubMed ID: 29092060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble klotho and autosomal dominant polycystic kidney disease.
    Pavik I; Jaeger P; Ebner L; Poster D; Krauer F; Kistler AD; Rentsch K; Andreisek G; Wagner CA; Devuyst O; Wüthrich RP; Schmid C; Serra AL
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):248-57. PubMed ID: 22193235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decreased soluble Klotho level with normal eGFR, FGF23, serum phosphate, and FEP in an ADPKD patient with enlarged kidneys due to multiple cysts.
    Kanai T; Shiizaki K; Betsui H; Aoyagi J; Yamagata T
    CEN Case Rep; 2018 Nov; 7(2):259-263. PubMed ID: 29767399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
    Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL
    Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 23 and soluble Klotho in patients with autosomal dominant polycystic kidney disease.
    Akiyama K; Mochizuki T; Kataoka H; Tsuchiya K; Nitta K
    Nephrology (Carlton); 2017 Nov; 22(11):848-853. PubMed ID: 27450645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.
    Bienaimé F; Ambolet A; Aussilhou B; Brazier F; Fouchard M; Viau A; Barre P; Tissier AM; Correas JM; Paradis V; Terzi F; Friedlander G; Knebelmann B; Joly D; Prié D
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2319-2328. PubMed ID: 29618028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease.
    Mekahli D; Bacchetta J
    Pediatr Nephrol; 2013 Nov; 28(11):2089-96. PubMed ID: 23340856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A distinct bone phenotype in ADPKD patients with end-stage renal disease.
    Evenepoel P; Claes K; Cavalier E; Meijers B; Stenvinkel P; Behets G; Jankowska M; D'Haese P; Bammens B
    Kidney Int; 2019 Feb; 95(2):412-419. PubMed ID: 30665572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease.
    Sari F; Inci A; Dolu S; Ellidag HY; Cetinkaya R; Ersoy FF
    J Investig Med; 2017 Feb; 65(2):358-362. PubMed ID: 27733443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
    Wang K; Zelnick LR; Chen Y; Hoofnagle AN; Watnick T; Seliger S; Kestenbaum B
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):80-88. PubMed ID: 31628117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineral bone disease in autosomal dominant polycystic kidney disease.
    Gitomer B; Pereira R; Salusky IB; Stoneback JW; Isakova T; Cai X; Dalrymple LS; Ofsthun N; You Z; Malluche HH; Maddux F; George D; Torres V; Chapman A; Steinman TI; Wolf M; Chonchol M
    Kidney Int; 2021 Apr; 99(4):977-985. PubMed ID: 32926884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone and Mineral Metabolism in Children with Nephropathic Cystinosis Compared with other CKD Entities.
    Ewert A; Leifheit-Nestler M; Hohenfellner K; Büscher A; Kemper MJ; Oh J; Billing H; Thumfart J; Stangl G; Baur AC; Föller M; Feger M; Weber LT; Acham-Roschitz B; Arbeiter K; Tönshoff B; Zivicnjak M; Haffner D
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32413117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial dysfunction in early autosomal dominant polycystic kidney disease independent of fibroblast growth factor 23.
    Yildiz A; Gul CB; Ersoy A; Asiltas B; Ermurat S; Dogan S; Karaagac K; Sag S; Oruc A; Aktas N; Ocakoglu G; Dogan I; Gullulu S; Gullulu M
    Iran J Kidney Dis; 2014 Nov; 8(6):443-9. PubMed ID: 25362218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Regulation of mineral metabolism and mineralization by FGF23].
    Fukumoto S
    Clin Calcium; 2015 May; 25(5):687-91. PubMed ID: 25926572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease.
    Helal I; Reed B; McFann K; Yan XD; Fick-Brosnahan GM; Cadnapaphornchai M; Schrier RW
    Clin J Am Soc Nephrol; 2011 Oct; 6(10):2439-43. PubMed ID: 21903987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease.
    Seeman T; Fořtová M; Sopko B; Průša R; Pohl M; John U
    Ann Clin Biochem; 2019 Jan; 56(1):90-94. PubMed ID: 29874928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lithium clearance in polycystic kidney disease].
    Merta M; Tesar V; Zabka J; Zima T
    Sb Lek; 1994; 95(1):19-23. PubMed ID: 8571068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.